** Shares of insulin delivery device maker Beta Bionics BBNX.O jump as much as 41.2% in their Nasdaq debut
** Stock opens for trading at $22, valuing the Irvine, California-based company at $943.6 mln
** BBNX sold 12 mln shares, 60% more than initially offered, at the top end of its marketed range of $16 and $17 to raise $204 mln
** IPO was twice upsized and follows medical device maker CeriBell's CBLL.O strong debut last year, underscoring a gradual recovery in medtech listings
** BBNX's strong show comes in the aftermath of underwhelming debuts by major IPO candidates including LNG exporter Venture Global VG.N and pork producer Smithfield Foods SFD.O
** BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street were the underwriters for the offering
** Asset manager Wellington Management, an existing Beta shareholder, had agreed to purchase $17 million worth of the company's shares in a concurrent private placement at the IPO price
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.